Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Margitta Worm, Charles Lynde et al.|British Journal of Dermatology|2020Cited by 590
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, James V. Cassella, Maryanne M. Senna et al.|Journal of the American Academy of Dermatology|2024Cited by 79